1887

Chapter 55 : Rubella Virus

Author: David W. Kimberlin
Content Type: Reference
Publication Year: 2009

Category: Viruses and Viral Pathogenesis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Rubella Virus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap55-1.gif /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap55-2.gif

Abstract:

Rubella virus is the sole member of the genus of the family. The other genus in the family of is . In contrast to the alphaviruses, which replicate in arthropods and in vertebrates, rubella virus has no invertebrate hosts. As humans are the only known natural host for rubella virus, the virus must circulate continuously within populations of people between periods of epidemics. While direct cellular destruction by rubella virus accounts for some of the tissue damage seen in congenital rubella syndrome, vascular injury and resulting insufficiency are more important in the pathogenesis of congenital defects. The consequences of in utero rubella virus infection can be considered broadly as belonging to one of three categories: (i) signs and symptoms that are transiently apparent in affected infants, (ii) permanent manifestations that are noted within the first year of life, and (iii) manifestations of congenital rubella that are delayed in onset until later in life (2 years of age to adulthood). Rubella virus infection is definitively diagnosed by isolation of rubella virus in tissue culture, using one of several cell lines and primary cell strains. Viral interference in African green monkey kidney (AGMK) cells is one common culture technique by which the presence of rubella virus is demonstrated.

Citation: Kimberlin D. 2009. Rubella Virus, p 1275-1289. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch55

Key Concept Ranking

Rubella virus
0.49972305
Enzyme-Linked Immunosorbent Assay
0.46283197
Major Histocompatibility Complex
0.4499175
0.49972305
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Rubella Virus
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch55-1,webId=/content/author/10.1128/9781555815981.ch55-1,properties={foaf_givenname=David W., foaf_name=David W. Kimberlin, foaf_surname=Kimberlin}]]
Citation: Kimberlin D. 2009. Rubella Virus, p 1275-1289. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch55
/content/10.1128/9781555815981.ch55.ch55fig01
FIGURE 1
Number of reported cases of rubella and congenital rubella syndrome (CRS), by year, and chronology of rubella vaccination recommendations by the Advisory Committee on Immunization Practices, United States, 1966 to 2004. *, 1969—first official recommendations are published for the use of rubella vaccine. Vaccination is recommended for children aged 1 year to puberty. †, 1978—recommendations for vaccination are expanded to include adolescents and certain adults, particularly females. Vaccination is recommended for adolescent or adult females and males in populations in colleges, certain places of employment (e.g., hospitals), and military bases. §, 1981—recommendations place increased emphasis on vaccination of susceptible persons in training and educational settings (e.g., universities or colleges) and military settings and vaccination of workers in health care settings. ¶, 1984—recommendations are published for vaccination of workers in day care centers, schools, colleges, companies, government offices, and industrial sites. Providers are encouraged to conduct prenatal testing and postpartum vaccination of susceptible women. Recommendations for vaccination are expanded to include susceptible persons who travel abroad. **, 1990—recommendations include implementation of a new two-dose schedule for MMR vaccine. (Modified from reference .)
10.1128/9781555815981/f1277-01_thmb.gif
10.1128/9781555815981/f1277-01.gif
Image of FIGURE 1
FIGURE 1

Number of reported cases of rubella and congenital rubella syndrome (CRS), by year, and chronology of rubella vaccination recommendations by the Advisory Committee on Immunization Practices, United States, 1966 to 2004. *, 1969—first official recommendations are published for the use of rubella vaccine. Vaccination is recommended for children aged 1 year to puberty. †, 1978—recommendations for vaccination are expanded to include adolescents and certain adults, particularly females. Vaccination is recommended for adolescent or adult females and males in populations in colleges, certain places of employment (e.g., hospitals), and military bases. §, 1981—recommendations place increased emphasis on vaccination of susceptible persons in training and educational settings (e.g., universities or colleges) and military settings and vaccination of workers in health care settings. ¶, 1984—recommendations are published for vaccination of workers in day care centers, schools, colleges, companies, government offices, and industrial sites. Providers are encouraged to conduct prenatal testing and postpartum vaccination of susceptible women. Recommendations for vaccination are expanded to include susceptible persons who travel abroad. **, 1990—recommendations include implementation of a new two-dose schedule for MMR vaccine. (Modified from reference .)

Citation: Kimberlin D. 2009. Rubella Virus, p 1275-1289. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch55
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch55.ch55fig02
FIGURE 2
Likelihood and outcome of congenital rubella syndrome as a function of time of acquisition of maternal rubella virus infection. Hatched bars, rate of fetal infection; striped bars, rate of defects in infected persons; diamonds, overall risk of defects after maternal infection. (Adapted from reference with permission.)
10.1128/9781555815981/f1278-01_thmb.gif
10.1128/9781555815981/f1278-01.gif
Image of FIGURE 2
FIGURE 2

Likelihood and outcome of congenital rubella syndrome as a function of time of acquisition of maternal rubella virus infection. Hatched bars, rate of fetal infection; striped bars, rate of defects in infected persons; diamonds, overall risk of defects after maternal infection. (Adapted from reference with permission.)

Citation: Kimberlin D. 2009. Rubella Virus, p 1275-1289. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch55
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch55.ch55fig03
FIGURE 3
Schematic of the immune response in acute rubella virus infection. Values on the axis indicate number of days. RIA, radioimmunoassay; EIA, enzyme immunoassay; HI, hemagglutination inhibition; LA, latex agglutination; FIA/FIAX and IFA, immunofluorescence; Nt, neutralization; PHA, passive agglutination. (Reprinted from reference with permission of Elsevier.)
10.1128/9781555815981/f1279-01_thmb.gif
10.1128/9781555815981/f1279-01.gif
Image of FIGURE 3
FIGURE 3

Schematic of the immune response in acute rubella virus infection. Values on the axis indicate number of days. RIA, radioimmunoassay; EIA, enzyme immunoassay; HI, hemagglutination inhibition; LA, latex agglutination; FIA/FIAX and IFA, immunofluorescence; Nt, neutralization; PHA, passive agglutination. (Reprinted from reference with permission of Elsevier.)

Citation: Kimberlin D. 2009. Rubella Virus, p 1275-1289. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch55
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch55.ch55fig04
FIGURE 4
Schematic of the immune response in the mother, fetus, and infant after maternal and fetal rubella virus infections in the first trimester of pregnancy. (Reprinted from reference with permission of Elsevier.)
10.1128/9781555815981/f1280-01_thmb.gif
10.1128/9781555815981/f1280-01.gif
Image of FIGURE 4
FIGURE 4

Schematic of the immune response in the mother, fetus, and infant after maternal and fetal rubella virus infections in the first trimester of pregnancy. (Reprinted from reference with permission of Elsevier.)

Citation: Kimberlin D. 2009. Rubella Virus, p 1275-1289. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch55
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch55.ch55fig05
FIGURE 5
(Left) Provisional zones of calcification are poorly defined and irregular. Radiolucent defects are present in metaphyses of femora and tibiae and the parallel long axis of the bone. (Right) Lower extremities 2 months later show nearly complete disappearance of osseous abnormalities. (Reprinted from reference with permission of the American Medical Association.)
10.1128/9781555815981/f1282-01_thmb.gif
10.1128/9781555815981/f1282-01.gif
Image of FIGURE 5
FIGURE 5

(Left) Provisional zones of calcification are poorly defined and irregular. Radiolucent defects are present in metaphyses of femora and tibiae and the parallel long axis of the bone. (Right) Lower extremities 2 months later show nearly complete disappearance of osseous abnormalities. (Reprinted from reference with permission of the American Medical Association.)

Citation: Kimberlin D. 2009. Rubella Virus, p 1275-1289. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch55
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815981.ch55
1. Alain, R.,, F. Nadon,, C. Seguin,, P. Payment, and, M. Trudel. 1987. Rapid virus subunit visualization by direct sedimentation of samples on electron microscope grids. J. Virol. Methods 16: 209– 216.
2. American Academy of Pediatrics. 2006. Rubella, p. 574–579. In L. K. Pickering (ed.), 2006 Red Book: Report of the Committee on Infectious Diseases, 26th ed. American Academy of Pediatrics, Elk Grove Village, IL.
3. Armstrong, R. D.,, A. Sinclair,, G. O’Keeffe, and, R. Grahame. 1985. Interferon treatment of chronic rubella associated arthritis. Clin. Exp. Rheumatol. 3: 93– 94.
4. Arvin, A. M.,, N. J. Schmidt,, K. Cantell, and, T. C. Merigan. 1982. Alpha interferon administration to infants with congenital rubella. Antimicrob. Agents Chemother. 21: 259– 261.
5. Bardeletti, G.,, N. Kessler, and, M. Aymard-Henry. 1975. Morphology, biochemical analysis and neuraminidase activity of rubella virus. Arch. Virol. 49: 175– 186.
6. Best, J. M.,, and J. E. Banatvala. 1970. Studies on rubella virus strain variation by kinetic haemagglutination-inhibition tests. J. Gen. Virol. 9: 215– 223.
7. Bosma, T. J.,, J. Etherington,, S. O’Shea,, K. Corbett,, F. Cottam,, L. Holt,, J. E. Banatvala, and, J. M. Best. 1998. Rubella virus and chronic joint disease: is there an association? J. Clin. Microbiol. 36: 3524– 3526.
8. Bottiger, B.,, and I. P. Jensen. 1997. Maturation of rubella IgG avidity over time after acute rubella infection. Clin. Diagn. Virol. 8: 105– 111.
9. Bowden, D. S.,, J. S. Pedersen,, B. H. Toh, and, E. G. Westaway. 1987. Distribution by immunofluorescence of viral products and actin-containing cytoskeletal filaments in rubella virus-infected cells. Arch. Virol. 92: 211– 219.
10. Brown, G. C.,, H. F. Maassab,, J. A. Veronelli, and, T. J. Francis, Jr. 1964. Rubella antibodies in human serum: detection by the indirect fluorescent antibody technic. Science 145: 943– 945.
11. Buimovici-Klein, E.,, P. B. Lang,, P. R. Ziring, and, L. Z. Cooper. 1979. Impaired cell-mediated immune response in patients with congenital rubella: correlation with gestational age at time of infection. Pediatrics 64: 620– 626.
12. Center for Disease Control. 1976. Reported morbidity and mortality for the United States, 1975. Morb. Mortal. Wkly. Rep. 24: 2.
13. Centers for Disease Control. 1989. Rubella and congenital rubella syndrome—United States, 1985–1988. Morb. Mortal. Wkly. Rep. 38: 173– 178.
14. Centers for Disease Control and Prevention. 1994. Rubella and congenital rubella syndrome—United States, January 1, 1991–May 7, 1994. Morb. Mortal. Wkly. Rep. 43: 391, 397– 401.
15. Centers for Disease Control and Prevention. 2005. Elimination of rubella and congenital rubella syndrome—United States, 1969–2004. Morb. Mortal. Wkly. Rep. 54: 279– 282.
16. Chagnon, A.,, and P. Laflamme. 1964. Effect of acidity on rubella virus. Can. J. Microbiol. 10: 501– 502.
17. Chantler, J. K. 1979. Rubella virus: intracellular polypeptide synthesis. Virology 98: 275– 278.
18. Chantler, J. K.,, D. M. da Roza,, M. E. Bonnie,, G. D. Reid, and, D. K. Ford. 1985. Sequential studies on synovial lymphocyte stimulation by rubella antigen, and rubella virus isolation in an adult with persistent arthritis. Ann. Rheum. Dis. 44: 564– 568.
19. Chantler, J. K.,, A. J. Tingle, and, R. E. Petty. 1985. Persistent rubella virus infection associated with chronic arthritis in children. N. Engl. J. Med. 313: 1117– 1123.
20. Cherry, J. D. 1992. Rubella, p. 1792–1817. In R. D. Feigin and, J. D. Cherry (ed.), Textbook of Pediatric Infectious Diseases, 3rd ed. The W. B. Saunders Co., Philadelphia, PA.
21. Clarke, M.,, G. C. Schild,, J. Boustred,, I. A. McGregor, and, K. Williams. 1980. Epidemiological studies of rubella virus in a tropical African community. Bull. W.H.O. 58: 931– 935.
22. Clarke, W. L.,, K. A. Shaver,, G. M. Bright,, A. D. Rogol, and, W. E. Nance. 1984. Autoimmunity in congenital rubella syndrome. J. Pediatr. 104: 370– 373.
23. Cooper, L. Z. 1968. Rubella: a preventable cause of birth defects, p. 23. In D. Bergman (ed.), Intrauterine Infections. The National Foundation, New York, NY.
24. Cooper, L. Z.,, A. L. Florman,, P. R. Ziring, and, S. Krugman. 1971. Loss of rubella hemagglutination inhibition antibody in congenital rubella. Failure of seronegative children with congenital rubella to respond to HPV-77 rubella vaccine. Am. J. Dis. Child. 122: 397– 403.
25. Cooper, L. Z.,, S. R. Preblud, and, C. A. Alford, Jr. 1995. Rubella, p. 268–311. In J. S. Remington and, J. O. Klein (ed.), Infectious Diseases of the Fetus and Newborn Infant, 4th ed. The W. B. Saunders Co., Philadelphia, PA.
26. Cradock-Watson, J. E.,, and M. K. Ridehalgh. 1976. Specific immunoglobulins in infants with the congenital rubella syndrome. J. Hyg. 76: 109– 123.
27. Cradock-Watson, J. E.,, M. K. Ridehalgh,, M. J. Anderson,, J. R. Pattison, and, H. O. Kangro. 1980. Fetal infection resulting from maternal rubella after the first trimester of pregnancy. J. Hyg. 85: 381– 391.
28. Cubie, H.,, and E. Edmond. 1985. Comparison of five different methods of rubella IgM antibody testing. J. Clin. Pathol. 38: 203– 207.
29. Cunningham, A. L.,, and J. R. Fraser. 1985. Persistent rubella virus infection of human synovial cells cultured in vitro. J. Infect. Dis. 151: 638– 645.
30. Cutts, F. T.,, and E. Vynnycky. 1999. Modelling the incidence of congenital rubella syndrome in developing countries. Int. J. Epidemiol. 28: 1176– 1184.
31. D’Angio, C. T.,, P. A. Boohene,, A. Mowrer,, S. Audet,, M. A. Menegus,, D. S. Schmid, and, J. A. Beeler. 2007. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants. Pediatrics 119: e574– e579.
32. Das, B. D.,, P. Lakhani,, J. B. Kurtz,, N. Hunter,, B. E. Watson,, K. A. Cartwright,, E. O. Caul, and, A. P. Roome. 1990. Congenital rubella after previous maternal immunity. Arch. Dis. Child. 65: 545– 546.
33. Davis, W. J.,, H. E. Larson,, J. P. Simsarian,, P. D. Parkman, and, H. M. Meyer, Jr. 1971. A study of rubella immunity and resistance to infection. JAMA 215: 600– 608.
34. de Groot-Mijnes, J. D.,, L. de Visser,, A. Rothova,, M. Schuller,, A. M. van Loon, and, A. J. Weersink. 2006. Rubella virus is associated with Fuchs heterochromic iridocyclitis. Am. J. Ophthalmol. 141: 212– 214.
35. DeStefano, F. 2007. Vaccines and autism: evidence does not support a causal association. Clin. Pharmacol. Ther. 82: 756– 759.
36. Doege, T. C.,, and K. S. Kim. 1967. Studies of rubella and its prevention with immune globulin. JAMA 200: 584– 590.
37. Driscoll, S. G. 1969. Histopathology of gestational rubella. Am. J. Dis. Child. 118: 49– 53.
38. Emminghaus, H. 1870. Über Rubeolen. Jahrb. Kinder 4: 47– 59.
39. Enders, G.,, and F. Knotek. 1989. Rubella IgG total antibody avidity and IgG subclass-specific antibody avidity assay and their role in the differentiation between primary rubella and rubella reinfection. Infection 17: 218– 226.
40. Erickson, C. A. 1944. Rubella early in pregnancy causing congenital malformations of eyes and heart. J. Pediatr. 25: 281– 283.
41. Evans, M. W. 1944. Congenital dental defects in infants subsequent to maternal rubella during pregnancy. Med. J. Aust. 2: 225– 228.
42. Fenner, F. 1998. Candidate viral diseases for elimination or eradication. Bull. W.H.O. 76 (Suppl. 2) : 68– 70.
43. Forbes, J. A. 1969. Rubella: historical aspects. Am. J. Dis. Child. 118: 5– 11.
44. Forcheimer, F. 1898. The enanthem of German measles. Trans. Am. Pediatr. Soc. 10: 118– 128.
45. Ford, D. K.,, G. D. Reid,, A. J. Tingle,, L. A. Mitchell, and, M. Schulzer. 1992. Sequential follow up observations of a patient with rubella associated persistent arthritis. Ann. Rheum. Dis. 51: 407– 410.
46. Forrest, J. M.,, F. M. Turnbull,, G. F. Sholler,, R. E. Hawker,, F. J. Martin,, T. T. Doran, and, M. A. Burgess. 2002. Gregg’s congenital rubella patients 60 years later. Med. J. Aust. 177: 664– 667.
47. Forsgren, M.,, and L. Soren. 1985. Subclinical rubella reinfection in vaccinated women with rubella-specific IgM response during pregnancy and transmission of virus to the fetus. Scand. J. Infect. Dis. 17: 337– 341.
48. Gale, J. L.,, R. Detels,, K. S. Kim,, R. P. Beasley,, K. P. Chen, and, J. T. Grayston. 1972. The epidemiology of rubella on Taiwan. 3. Family studies in cities of high and low attack rates. Int. J. Epidemiol. 1: 261– 265.
49. Gershon, A. A. 1995. Rubella virus (German measles), p. 1459–1465. In G. L. Mandell,, J. E. Bennett, and, R. Dolin (ed.), Principles and Practice of Infectious Diseases, 4th ed. Churchill Livingstone, New York, NY.
50. Grangeot-Keros, L.,, J. Pillot,, F. Daffos, and, F. Forestier. 1988. Prenatal and postnatal production of IgM and IgA antibodies to rubella virus studied by antibody capture immunoassay. J. Infect. Dis. 158: 138– 143.
51. Grayston, J. T.,, J. L. Gale, and, R. H. Watten. 1972. The epidemiology of rubella on Taiwan. I. Introduction and description of the 1957–1958 epidemic. Int. J. Epidemiol. 1: 245– 252.
52. Greaves, W. L.,, W. A. Orenstein,, H. C. Stetler,, S. R. Preblud,, A. R. Hinman, and, K. J. Bart. 1982. Prevention of rubella transmission in medical facilities. JAMA 248: 861– 864.
53. Green, R. H.,, M. R. Balsamo,, J. P. Giles,, S. Krugman, and, G. S. Mirick. 1965. Studies of the natural history and prevention of rubella. Am. J. Dis. Child. 110: 348– 365.
54. Gregg, N. M. 1941. Congenital cataract following German measles in the mother. Trans. Ophthalmol. Soc. Aust. 3: 35– 46.
55. Gutierrez, J.,, M. J. Rodriguez,, F. De Ory,, G. Piedrola, and, M. C. Maroto. 1999. Reliability of low-avidity IgG and of IgA in the diagnosis of primary infection by rubella virus with adaptation of a commercial test. J. Clin. Lab. Anal. 13: 1– 4.
56. Habel, K. 1942. Transmission of rubella to Macacus mulatta monkeys. Public Health Rep. 57: 1126– 1139.
57. Hattis, R. P.,, S. B. Halstead,, K. L. Herrmann, and, J. J. Witte. 1973. Rubella in an immunized island population. JAMA 223: 1019– 1021.
58. Heggie, A. D.,, and F. C. Robbins. 1969. Natural rubella acquired after birth. Clinical features and complications. Am. J. Dis. Child. 118: 12– 17.
59. Hemphill, M. L.,, R. Y. Forng,, E. S. Abernathy, and, T. K. Frey. 1988. Time course of virus-specific macro-molecular synthesis during rubella virus infection in Vero cells. Virology 162: 65– 75.
60. Herne, V.,, K. Hedman, and, P. Reedik. 1997. Immunoglobulin G avidity in the serodiagnosis of congenital rubella syndrome. Eur. J. Clin. Microbiol. Infect. Dis. 16: 763– 766.
61. Hillenbrand, F. K. 1956. Rubella in a remote community. Lancet 271: 64– 66.
62. Hiro, Y.,, and S. Tasaka. 1938. Die Roteln sind eine Viruskrankheit. Monatsschr. Kinderheilkd. 76: 328– 332.
63. Hofmann, J.,, M. Kortung,, B. Pustowoit,, R. Faber,, U. Piskazeck, and, U. G. Liebert. 2000. Persistent fetal rubella vaccine virus infection following inadvertent vaccination during early pregnancy. J. Med. Virol. 61: 155– 158.
64. Holmes, I. H.,, M. C. Wark, and, M. F. Warburton. 1969. Is rubella an arbovirus? II. Ultrastructural morphology and development. Virology 37: 15– 25.
65. Homans, J. 1848. Roetheln, p. 370. Boston Society for Medical Improvement, Records of Meetings (manuscript). Boston Medical Library. Boston Society for Medical Improvements, Boston, MA.
66. Honeyman, M. C.,, D. C. Dorman,, M. A. Menser,, J. M. Forrest,, J. J. Guinan, and, P. Clark. 1975. HL-A antigens in congenital rubella and the role of antigens 1 and 8 in the epidemiology of natural rubella. Tissue Antigens 5: 12– 18.
67. Horstmann, D. M. 1969. Discussion paper: the use of primates in experimental viral infections—rubella and the rubella syndrome. Ann. N. Y. Acad. Sci. 162: 594– 597.
68. Horstmann, D. M. 1990. Rubella, p. 617. In A. S. Evans (ed.), Viral Infections of Humans: Epidemiology and Control, 3rd ed. Plenum Medical Book Company, New York, NY.
69. Horstmann, D. M. 1971. Rubella: the challenge of its control. J. Infect. Dis. 123: 640– 654.
70. Horstmann, D. M.,, H. Liebhaber,, G. L. Le Bouvier,, D. A. Rosenberg, and, S. B. Halstead. 1970. Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic. N. Engl. J. Med. 283: 771– 778.
71. Horstmann, D. M.,, J. T. Riordan,, M. Ohtawara, and, J. C. Niederman. 1965. A natural epidemic of rubella in a closed population: virological and epidemiological observations. Arch. Gesamte Virusforsch. 16: 483– 487.
72. Horton, R. 2004. A statement by the editors of The Lancet. Lancet 363: 820– 821.
73. HoTerry, L.,, G. M. Terry,, P. Londesborough,, K. R. Rees,, F. Wielaard, and, A. Denissen. 1988. Diagnosis of fetal rubella infection by nucleic acid hybridization. J. Med. Virol. 24: 175– 182.
74. Howe, C. J.,, and C. P. Howson. 1991. Adverse effects of pertussis and rubella vaccines. In C. J. Howe,, C. P. Howson, and, H. V. Fineberg (ed.), Adverse Effects of Pertussis and Rubella Vaccines. National Academy Press, Washington, DC.
75. Howson, C. P.,, M. Katz,, R. B. Johnston, Jr., and, H. V. Fineberg. 1992. Chronic arthritis after rubella vaccination. Clin. Infect. Dis. 15: 307– 312.
76. Immunization Safety Review Committee. 2004. Immunization Safety Review. In Institute of Medicine (ed.), Vaccines and Autism Board of Health Promotion and Disease Prevention. National Academy Press, Washington, DC.
77. Kimberlin, D. W. 1997. Rubella immunization. Pediatr. Ann. 26: 366– 370.
78. Krugman, S. E. 1969. International Conference on Rubella Immunization. Am. J. Dis. Child. 118: 2– 410.
79. Margolis, F. J.,, J. L. Wilson, and, F. H. Top. 1943. Post-rubella encephalomyelitis. Report of cases in Detroit and review of the literature. J. Pediatr. 23: 158– 165.
80. Martin, S. M. 1945. Congenital defects and rubella. Br. Med. J. 1: 855.
81. Martin du Pan, R.,, B. Koechli, and, A. Douath. 1972. Protection of nonimmune volunteers against rubella by intravenous administration of normal human gamma globulin. J. Infect. Dis. 126: 341– 344.
82. Maton, W. G. 1815. Some account of rash, liable to be mistaken for scarlatina. Med. Trans. R. Coll. Physicians 5: 149– 165.
83. Meissner, H. C.,, S. E. Reef, and, S. Cochi. 2006. Elimination of rubella from the United States: a milestone on the road to global elimination. Pediatrics 117: 933– 935.
84. Mellinger, A. K.,, J. D. Cragan,, W. L. Atkinson,, W. W. Williams,, B. Kleger,, R. G. Kimber, and, D. Tavris. 1995. High incidence of congenital rubella syndrome after a rubella outbreak. Pediatr. Infect. Dis. J. 14: 573– 578.
85. Meyer, H. M.,, Jr., H. E. Hopps,, P. D. Parkman, and, F. A. Ennis. 1978. Control of measles and rubella through use of attenuated vaccines. Am. J. Clin. Pathol. 70: 128– 135.
86. Meyer, H. M.,, Jr., P. D. Parkman,, T. E. Hobbins,, H. E. Larson,, W. J. Davis,, J. P. Simsarian, and, H. E. Hopps. 1969. Attenuated rubella viruses. Laboratory and clinical characteristics. Am. J. Dis. Child. 118: 155– 165.
87. Meyer, H. M.,, Jr., P. D. Parkman, and, T. C. Panos. 1966. Attenuated rubella virus. II. Production of an experimental live-virus vaccine and clinical trial. N. Engl. J. Med. 275: 575– 580.
88. Miki, N. P.,, and J. K. Chantler. 1992. Differential ability of wild-type and vaccine strains of rubella virus to replicate and persist in human joint tissue. Clin. Exp. Rheumatol. 10: 3– 12.
89. Miller, E.,, J. E. Cradock-Watson, and, T. M. Pollock. 1982. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet ii: 781– 784.
90. Miller, E.,, P. Waight,, C. P. Farrington,, N. Andrews,, J. Stowe, and, B. Taylor. 2001. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch. Dis. Child. 84: 227– 229.
91. Mori, T.,, and K. Shiozawa. 1985. Suppression of tuberculin hypersensitivity caused by rubella infection. Am. Rev. Respir. Dis. 131: 886– 888.
92. Mubareka, S.,, H. Richards,, M. Gray, and, G. A. Tipples. 2007. Evaluation of commercial rubella immunoglobulin G avidity assays. J. Clin. Microbiol. 45: 231– 233.
93. Murch, S. H.,, A. Anthony,, D. H. Casson,, M. Malik,, M. Berelowitz,, A. P. Dhillon,, M. A. Thomson,, A. Valentine,, S. E. Davies, and, J. A. Walker-Smith. 2004. Retraction of an interpretation. Lancet 363: 750.
94. Naeye, R. L.,, and W. Blanc. 1965. Pathogenesis of congenital rubella. JAMA 194: 1277– 1283.
95. Ovsyannikova, I. G.,, R. M. Jacobson,, J. E. Ryan,, N. Dhiman,, R. A. Vierkant, and, G. A. Poland. 2007. Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination. Clin. Vaccine Immunol. 14: 115– 122.
96. Ovsyannikova, I. G.,, R. M. Jacobson,, R. A. Vierkant,, V. S. Pankratz, and, G. A. Poland. 2007. HLA super-types and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 25: 3090– 3100.
97. Parkman, P. D.,, E. L. Buescher, and, M. S. Artenstein. 1962. Recovery of rubella virus from army recruits. Proc. Soc. Exp. Biol. Med. 111: 225– 230.
98. Parkman, P. D.,, E. L. Buescher,, M. S. Artenstein,, J. M. McCown,, F. K. Mundon, and, A. D. Druzd. 1964. Studies of rubella. I. Properties of the virus. J. Immunol. 93: 595– 607.
99. Parkman, P. D.,, P. E. Phillips,, R. L. Kirschstein, and, H. M. Meyer, Jr. 1965. Experimental rubella virus infection in the rhesus monkey. J. Immunol. 95: 743– 752.
100. Parkman, P. D.,, P. E. Phillips, and, H. M. Meyer, Jr. 1965. Experimental rubella virus infection in pregnant monkeys. Am. J. Dis. Child. 110: 390– 394.
101. Pattison, J. R. 1975. Persistence of specific IgM after natural infection with rubella virus. Lancet i: 185– 187.
102. Peckham, C. S. 1972. Clinical and laboratory study of children exposed in utero to maternal rubella. Arch. Dis. Child. 47: 571– 577.
103. Perkins, F. T. 1985. Licensed vaccines. Rev. Infect. Dis. 7 (Suppl. 1) : S73– S76.
104. Pettersson, R. F.,, C. Oker-Blom,, N. Kalkkinen,, A. Kallio,, I. Ulmanen,, L. Kaariainen,, P. Partanen, and, A. Vaheri. 1985. Molecular and antigenic characteristics and synthesis of rubella virus structural proteins. Rev. Infect. Dis. 7 (Suppl. 1) : S140– S149.
105. Plotkin, S. A. 2006. The history of rubella and rubella vaccination leading to elimination. Clin. Infect. Dis. 43 (Suppl. 3) : S164– S168.
106. Plotkin, S. A. 1988. Rubella vaccine, p. 235–262. In S. A. Plotkin and, E. A. Mortimer, Jr. (ed.), Vaccines. The W. B. Saunders Co., Philadelphia, PA.
107. Plotkin, S. A. 1969. Rubella virus, p. 364. In E. H. Lennette and, N. J. Schmidt (ed.), Diagnostic Procedures for Viral and Rickettsial Infections. American Public Health Association, New York, NY.
108. Plotkin, S. A.,, J. D. Farquhar,, M. Katz, and, F. Buser. 1969. Attenuation of RA 27-3 rubella virus in WI-38 human diploid cells. Am. J. Dis. Child. 118: 178– 185.
109. Plotkin, S. A.,, M. Katz, and, J. F. Cordero. 1999. The eradication of rubella. JAMA 281: 561– 562.
110. Plotkin, S. A.,, R. M. Klaus, and, J. P. Whitely. 1966. Hypogammaglobulinemia in an infant with congenital rubella syndrome; failure of 1-adamantane to stop virus excretion. J. Pediatr. 69: 1085– 1091.
111. Pollard, R. B.,, and E. A. Edwards. 1975. Epidemiologic survey of rubella in a military recruit population. Am. J. Epidemiol. 101: 431– 437.
112. Prinzie, A.,, C. Huygelen,, J. Gold,, J. Farquhar, and, J. McKee. 1969. Experimental live attenuated rubella virus vaccine. Clinical evaluation of Cendehill strain. Am. J. Dis. Child. 118: 172– 177.
113. Public Health Laboratory Service Working Party on Rubella. 1970. Studies of the effect of immunoglobulin on rubella in pregnancy. Report of the Public Health Laboratory Service Working Party on Rubella. Br. Med. J. 2: 497– 500.
114. Rawls, W. E.,, A. Phillips,, J. L. Melnick, and, M. M. Desmond. 1967. Persistent virus infection in congenital rubella. Arch. Ophthalmol. 77: 430– 433.
115. Ray, P.,, S. Black,, H. Shinefield,, A. Dillon,, J. Schwalbe,, S. Holmes,, S. Hadler,, R. Chen,, S. Cochi, and, S. Wassilak for the Vaccine Safety Datalink Team. 1997. Risk of chronic arthropathy among women after rubella vaccination. JAMA 278: 551– 556.
116. Roush, S. W.,, T. V. Murphy, and the Vaccine-Preventable Disease Working Group. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298: 2155– 2163.
117. Rudolph, A. J.,, E. B. Singleton,, H. S. Rosenberg,, D. B. Singer, and, C. A. Phillips. 1965. Osseous manifestations of the congenital rubella syndrome. Am. J. Dis. Child. 110: 428– 433.
118. Schiff, G. M.,, and M. S. Dine. 1965. Transmission of rubella from newborns. A controlled study among young adult women and report of an unusual case. Am. J. Dis. Child. 110: 447– 451.
119. Schiff, G. M.,, J. L. Sever, and, R. J. Huebner. 1965. Experimental rubella. Clinical and laboratory findings. Arch. Intern. Med. 116: 537– 543.
120. Schmidt, N. J.,, and B. Styk. 1968. Immunodiffusion reactions with rubella antigens. J. Immunol. 101: 210– 216.
121. Sedwick, W. D.,, and F. Sokol. 1970. Nucleic acid of rubella virus and its replication in hamster kidney cells. J. Virol. 5: 478– 489.
122. Sever, J. L.,, R. J. Huebner,, G. A. Castellano,, P. S. Sarma,, A. Fabiyi,, G. M. Schiff, and, C. L. Cusumano. 1965. Rubella complement fixation test. Science 148: 385– 387.
123. Sever, J. L.,, G. W. Meier,, W. F. Windle,, G. M. Schiff,, G. R. Monif, and, A. Fabiyi. 1966. Experimental rubella in pregnant rhesus monkeys. J. Infect. Dis. 116: 21– 26.
124. Sever, J. L.,, M. A. South, and, K. A. Shaver. 1985. Delayed manifestations of congenital rubella. Rev. Infect. Dis. 7 (Suppl. 1) : S164– S169.
125. Shapiro, L. 1965. The numbered diseases: first through sixth. JAMA 194: 680.
126. Siemerink, M. J.,, K. M. Sijssens,, J. D. de Groot-Mijnes, and, J. H. de Boer. 2007. Rubella virus-associated uveitis in a nonvaccinated child. Am. J. Ophthalmol. 143: 899– 900.
127. Singh, V. K.,, A. J. Tingle, and, M. Schulzer. 1986. Rubella-associated arthritis. II. Relationship between circulating immune complex levels and joint manifestations. Ann. Rheum. Dis. 45: 115– 119.
128. Stewart, G. L.,, P. D. Parkman,, H. E. Hopps,, R. D. Douglas,, J. P. Hamilton, and, H. M. Meyer, Jr. 1967. Rubella-virus hemagglutination-inhibition test. N. Engl. J. Med. 276: 554– 557.
129. Swan, C.,, A. L. Tostevin,, H. Mayo, et al. 1944. Further observations on congenital defects in infants following infectious diseases during pregnancy, with special reference to rubella. Med. J. Aust. 1: 409– 413.
130. Swan, C.,, A. L. Tostevin,, B. Moore, et al. 1943. Congenital defects in infants following infectious diseases during pregnancy. With special reference to the relationship between German measles and cataract, deaf-mutism, heart disease and microcephaly, and to the period of pregnancy in which the occurrence of rubella is followed by congenital abnormalities. Med. J. Aust. 2: 201– 210.
131. Terry, G. M.,, L. Ho-Terry,, R. C. Warren,, C. H. Rodeck,, A. Cohen, and, K. R. Rees. 1986. First trimester prenatal diagnosis of congenital rubella: a laboratory investigation. Br. Med. J. (Clin. Res. Ed.) 292: 930– 933.
132. Tingle, A. J.,, M. Allen,, R. E. Petty,, G. D. Kettyls, and, J. K. Chantler. 1986. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann. Rheum. Dis. 45: 110– 114.
133. Tingle, A. J.,, L. A. Mitchell,, M. Grace,, P. Middleton,, R. Mathias,, L. MacWilliam, and, A. Chalmers. 1997. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet 349: 1277– 1281.
134. Tondury, G.,, and D. W. Smith. 1966. Fetal rubella pathology. J. Pediatr. 68: 867– 879.
135. Townsend, J. J.,, J. R. Baringer,, J. S. Wolinsky,, N. Malamud,, J. P. Mednick,, H. S. Panitch,, R. A. Scott,, L. Oshiro, and, N. E. Cremer. 1975. Progressive rubella panencephalitis. Late onset after congenital rubella. N. Engl. J. Med. 292: 990– 993.
136. Transactions of the International Congress of Medicine. 1881. Trans. Intl. Congr. Med. 4: 14– 34.
137. Ueda, K.,, F. Sasaki,, K. Tokugawa,, K. Segawa, and, H. Fujii. 1984. The 1976–1977 rubella epidemic in Fukuoka city in southern Japan: epidemiology and incidences of complications among 80,000 persons who were school children at 28 primary schools and their family members. Biken J. 27: 161– 168.
138. Ueda, K.,, K. Tokugawa,, J. Fukushige,, H. Yoshikawa, and, S. Nonaka. 1987. Hemagglutination inhibition antibodies in congenital rubella syndrome. A 17-year follow-up in the Ryukyu Islands. Am. J. Dis. Child. 141: 211– 212.
139. Vaheri, A.,, and T. Vesikari. 1971. Small size rubella virus antigens and soluble immune complexes: analysis by the platelet aggregation technique. Arch. Gesamte Virusforsch. 35: 10– 24.
140. Veale, H. 1866. History of epidemic of Rotheln, with observations on its pathology. Edinb. Med. J. 12: 404– 414.
141. Vejtorp, M. 1978. Enzyme-linked immunosorbent assay for determination of rubella IgG antibodies. Acta Pathol. Microbiol. Scand. Sect. B 86B: 387– 392.
142. Vergani, D.,, P. Morgan-Capner,, E. T. Davies,, A. W. Anderson,, D. E. Tee, and, J. R. Pattison. 1980. Joint symptoms, immune complexes, and rubella. Lancet ii: 321– 322.
143. Wakefield, A. J.,, S. H. Murch,, A. Anthony,, J. Linnell,, D. M. Casson,, M. Malik,, M. Berelowitz,, A. P. Dhillon,, M. A. Thomson,, P. Harvey,, A. Valentine,, S. E. Davies, and, J. A. Walker-Smith. 1998. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351: 637– 641.
144. Wallis, C.,, J. L. Melnick, and, F. Rapp. 1965. Different effects of MgC12 and MgSO4 on the thermostability of viruses. Virology 26: 694– 699.
145. Watson, J. C.,, S. C. Hadler,, C. A. Dykewicz,, S. Reef, and, L. Phillips. 1998. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. Recomm. Rep. 47: 1– 57.
146. Weller, T. H.,, and F. A. Neva. 1962. Propagation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc. Soc. Exp. Biol. Med. 111: 215– 225.
147. Wesselhoeft, C. 1947. Rubella (German measles). N. Engl. J. Med. 236: 943– 950.
148. Wesselhoeft, C. 1947. Rubella (German measles) (concluded). N. Engl. J. Med. 236: 978– 988.
149. Wilkins, J.,, J. M. Leedom,, B. Portnoy, and, M. A. Salvatore. 1969. Reinfection with rubella virus despite live vaccine induced immunity. Trials of HPV-77 and HPV-80 live rubella virus vaccines and subsequent artificial and natural challenge studies. Am. J. Dis. Child. 118: 275– 294.
150. Wilkins, J.,, J. M. Leedom,, M. A. Salvatore, and, B. Portnoy. 1972. Clinical rubella with arthritis resulting from reinfection. Ann. Intern. Med. 77: 930– 932.
151. Willan (cited by G. Gregory). 1843. Lectures on the Eruptive Fevers, p. 102. Henry Renshaw, London, United Kingdom.
152. Witte, J. J.,, A. W. Karchmer,, G. Case,, K. L. Herrmann,, E. Abrutyn,, I. Kassanoff, and, J. S. Neill. 1969. Epidemiology of rubella. Am. J. Dis. Child. 118: 107– 111.
153. Wolinsky, J. S. 1990. Rubella, p. 815–838. In B. N. Fields,, D. M. Knipe,, R. M. Chanock,, M. S. Hirsch,, J. L. Melnick,, T. P. Monath, and, B. Roizman (ed.), Virology, 2nd ed. Raven Press, New York, NY.
154. Wolinsky, J. S.,, P. C. Dau,, E. Buimovici-Klein,, J. Mednick,, B. O. Berg,, P. B. Lang, and, L. Z. Cooper. 1979. Progressive rubella panencephalitis: immunovirological studies and results of isoprinosine therapy. Clin. Exp. Immunol. 35: 397– 404.
155. Zhao, L. H.,, Y. Y. Ma,, H. Wang,, S. P. Zhao,, W. M. Zhao,, H. Li, and, L. Y. Wang. 2006. Establishment and application of a TaqMan real-time quantitative reverse transcription-polymerase chain reaction assay for rubella virus RNA. Acta Biochim. Biophys. Sin. 38: 731– 736.
156. Zheng, D. P.,, T. K. Frey,, J. Icenogle,, S. Katow,, E. S. Abernathy,, K. J. Song,, W. B. Xu,, V. Yarulin,, R. G. Desjatskova,, Y. Aboudy,, G. Enders, and, M. Croxson. 2003. Global distribution of rubella virus genotypes. Emerg. Infect. Dis. 9: 1523– 1530.

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error